[go: up one dir, main page]

MX2009005652A - Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. - Google Patents

Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.

Info

Publication number
MX2009005652A
MX2009005652A MX2009005652A MX2009005652A MX2009005652A MX 2009005652 A MX2009005652 A MX 2009005652A MX 2009005652 A MX2009005652 A MX 2009005652A MX 2009005652 A MX2009005652 A MX 2009005652A MX 2009005652 A MX2009005652 A MX 2009005652A
Authority
MX
Mexico
Prior art keywords
retigabine
analogues
potassium channel
channel modulators
diamino bicyclic
Prior art date
Application number
MX2009005652A
Other languages
English (en)
Inventor
Huanming Chen
Jim Zhen Wu
Jenny Song
Jean-Michel Vernier
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of MX2009005652A publication Critical patent/MX2009005652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/30—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se refiere a compuestos de fórmula (I), (ver fórmula (I)) en donde G es -O-, -S-, -C(g1)(g2)-, o -NH-, y n =1, 2, o 3; dichos compuestos modulan los canales de potasio; los compuestos son útiles para el tratamiento y prevención de enfermedades y trastornos que son afectados por la modulación de canales de ion de potasio; una de esas condiciones son los trastornos de convulsión.
MX2009005652A 2006-11-28 2007-11-28 Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. MX2009005652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86748206P 2006-11-28 2006-11-28
PCT/US2007/024607 WO2008066900A1 (en) 2006-11-28 2007-11-28 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Publications (1)

Publication Number Publication Date
MX2009005652A true MX2009005652A (es) 2009-08-07

Family

ID=39223113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005652A MX2009005652A (es) 2006-11-28 2007-11-28 Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.

Country Status (15)

Country Link
US (1) US8030518B2 (es)
EP (1) EP2086925B1 (es)
JP (1) JP2010511052A (es)
KR (1) KR20090083479A (es)
CN (1) CN101578259A (es)
AT (1) ATE538084T1 (es)
AU (1) AU2007325629A1 (es)
BR (1) BRPI0719590A2 (es)
CA (1) CA2670966A1 (es)
EA (1) EA200900749A1 (es)
ES (1) ES2375417T3 (es)
IL (1) IL198905A0 (es)
MX (1) MX2009005652A (es)
NZ (1) NZ577740A (es)
WO (1) WO2008066900A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2011528666A (ja) * 2008-07-18 2011-11-24 バレアント プハルマセウトイカルス インターナショナル 放出調節製剤及びその使用方法
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
DE102009013611A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
BR112012018173A2 (pt) * 2010-01-20 2017-08-29 Valeant Pharmaceuticals Int "formulação de liberação modificada e método de uso"
EP2729176A1 (en) 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
ES2866324T3 (es) 2016-04-22 2021-10-19 Ono Pharmaceutical Co Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
JP2022553569A (ja) 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
CN114057641B (zh) * 2020-08-07 2025-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
WO2022173855A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) * 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3321582A1 (de) * 1983-06-15 1984-12-20 Basf Ag, 6700 Ludwigshafen Anilinderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
JP2583067B2 (ja) * 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) * 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (es) * 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) * 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
USRE38115E1 (en) * 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
EP0799051B1 (en) * 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
WO1999007411A1 (fr) * 1997-08-08 1999-02-18 Chugai Seiyaku Kabushiki Kaisha Remedes contre les complications du diabete
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
AU764921B2 (en) * 1998-12-14 2003-09-04 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
JP2002538221A (ja) * 1999-03-10 2002-11-12 ワーナー−ランバート・カンパニー 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
CA2367895A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
US6447010B1 (en) 1999-06-30 2002-09-10 Siemens Vdo Automotive Corporation Seat belt force sensor system
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
KR20020024300A (ko) 1999-07-06 2002-03-29 피터 지. 스트링거 편두통을 치료하기 위한 선택적 ｉＧｌｕＲ5 수용체 길항제
WO2001005767A1 (en) * 1999-07-20 2001-01-25 Novartis Ag Organic compounds
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
EP1208085B1 (en) * 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides as potassium channel openers
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) * 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
AU2003202115A1 (en) 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
ATE533743T1 (de) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7045551B2 (en) * 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
JP2004196702A (ja) * 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
JP4652816B2 (ja) * 2002-12-23 2011-03-16 アイシーエージェン インコーポレイテッド カリウムチャネルモジュレータとしてのキナゾリノン
ES2282701T3 (es) 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
EP1606247A1 (en) 2003-03-14 2005-12-21 H. Lundbeck A/S Substituted aniline derivatives
EP1613303A1 (en) * 2003-03-21 2006-01-11 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
MXPA05012463A (es) 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
WO2006054513A1 (ja) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PL2298766T3 (pl) 2005-03-03 2014-09-30 H Lundbeck As Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio

Also Published As

Publication number Publication date
CN101578259A (zh) 2009-11-11
NZ577740A (en) 2012-06-29
EP2086925A1 (en) 2009-08-12
US20080234334A1 (en) 2008-09-25
ES2375417T3 (es) 2012-02-29
BRPI0719590A2 (pt) 2014-01-21
EA200900749A1 (ru) 2009-12-30
JP2010511052A (ja) 2010-04-08
KR20090083479A (ko) 2009-08-03
US8030518B2 (en) 2011-10-04
WO2008066900A1 (en) 2008-06-05
IL198905A0 (en) 2010-02-17
AU2007325629A1 (en) 2008-06-05
CA2670966A1 (en) 2008-06-05
EP2086925B1 (en) 2011-12-21
ATE538084T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
MX2009005652A (es) Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.
MX2009002002A (es) Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
WO2020223538A8 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2008116912A3 (en) Purinyl derivatives and their use as potassium channel modulators
UA98482C2 (ru) Пуринильные производные и их применение в качестве модуляторов каналов калия
MX2010002712A (es) Compuestos que modulan calcio intracelular.
TW200607513A (en) Certain chemical entities, compositions, and methods
WO2010027875A3 (en) Compounds that modulate intracellular calcium
NO20082165L (no) Bifenylderivater som modulatorer av spenningsstyrte ionekanaler
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
MX2010004982A (es) Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt.
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
NO20081725L (no) Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler
PL1694318T3 (pl) (S)-2-N-propyloamino-5-hydroksytetrahydronaftalen jako D3-agonistyczny środek terapeutyczny
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
ATE400551T1 (de) Kaliumkanal-modulatoren
WO2008028935A3 (en) Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
WO2008092942A3 (en) Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
CR20210285A (es) DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVIDADES DE CANALES DE POTASIO Kv3

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration